Assembly Bio stock gains after exercising Gilead profit option
Assembly Biosciences (ASMB) shares rose 4.9% after-hours after exercising an option to share 40% of U.S. profits from its HSV HPI program with Gilead (GILD). The program includes GS-1179, expected to enter Phase 2 trials by late 2026. Assembly Bio could receive up to $280M in milestones and royalties, with a $75M payment from Gilead in Q4 2026.
How this was made
The 30-second read
Why it matters
The option exercise adds a new revenue stream and may improve cash runway, supporting a higher valuation.
Market read
ASMB's stock rose 4.9% after‑hours; traders may consider positioning ahead of the next trading session.
What to watch
Potential dilution from future milestone payments and Gilead's control over commercialization.
Background
Assembly Biosciences (ASMB) collaborates with Gilead on HSV antiviral candidates GS-1179 and GS-5366.
Ticker impact
Assembly Biosciences exercised its option to share 40% of U.S. development costs and profits on its HSV helicase‑primase inhibitor program with Gilead.
Potential short‑term upside as after‑hours price already rose ~5%; watch for continued pre‑market buying.
New contractual cash‑flow rights were disclosed for the first time, providing material upside to the micro‑cap.
Market effects
Highlights continued biotech‑pharma partnership model in antiviral space.
Limited to U.S. biotech investors; no broader regional effect.
Minor global impact; primarily relevant to niche antiviral investors.
Counterpoint
If the partnership fails to deliver clinical milestones, the cash‑flow upside may be overstated.
Key entities
- CompanyAssembly Biosciences Inc
Biotech firm developing HSV antiviral program.
- CompanyGilead Sciences Inc
Partner holding sole responsibility for development and commercialization.
